Larimar Therapeutics (LRMR) Assets Average (2014 - 2026)
Larimar Therapeutics' (LRMR) quarterly Assets Average came in at $166.6 million in Q4 2025, down 20.53% YoY from $209.6 million in Q4 2024, and down 1.23% on a QoQ basis from $168.7 million in Q3 2025.
Larimar Therapeutics (LRMR) Assets Average (2014 - 2026) Analysis & Trends
Larimar Therapeutics (LRMR) has 12 years of Assets Average data on file, last reported at $166.6 million in Q4 2025.
- Quarterly Assets Average fell 20.53% year-over-year to $166.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $166.6 million (down 20.53% YoY) and the FY2025 annual result came in at $173.0 million, up 16.85% from the prior year.
- Assets Average slipped to $166.6 million in Q4 2025, from $168.7 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $242.7 million in Q2 2024 to a low of $48.9 million in Q1 2021.
- A 5-year average of $132.6 million and a median of $119.0 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2021 — Assets Average surged 1653.57% — and 2025, when it tumbled 34.04%.
- Tracing LRMR's Assets Average over 5 years: stood at $83.3 million in 2021, then soared by 55.71% to $129.7 million in 2022, then declined by 22.95% to $99.9 million in 2023, then surged by 109.74% to $209.6 million in 2024, then dropped by 20.53% to $166.6 million in 2025.
- The last three Assets Average figures came in at $166.6 million (Q4 2025), $168.7 million (Q3 2025), and $160.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Larimar Therapeutics | 452.93 Mn | 296.66 Mn | - | 155.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 155.57 Mn |
| Dec 31, 2025 | 166.60 Mn |
| Sep 30, 2025 | 168.67 Mn |
| Jun 30, 2025 | 160.08 Mn |
| Mar 31, 2025 | 185.20 Mn |
| Dec 31, 2024 | 209.62 Mn |
| Sep 30, 2024 | 228.09 Mn |
| Jun 30, 2024 | 242.68 Mn |
| Mar 31, 2024 | 172.07 Mn |
| Dec 31, 2023 | 99.94 Mn |
| Sep 30, 2023 | 107.83 Mn |
| Jun 30, 2023 | 115.31 Mn |
| Mar 31, 2023 | 122.66 Mn |
| Dec 31, 2022 | 129.71 Mn |
| Sep 30, 2022 | 97.93 Mn |
| Jun 30, 2022 | 67.04 Mn |
| Mar 31, 2022 | 74.95 Mn |
| Dec 31, 2021 | 83.30 Mn |
| Sep 30, 2021 | 84.43 Mn |
| Jun 30, 2021 | 86.98 Mn |